

Building Long-Term Growth in Neurological and Rare Diseases

PROGRAM	INDICATION	MOLECULE DESCRIPTION	DISCOVERY	IND ENABLING	PHASE 1	PHASE 2	PHASE 3	LAUNCHED
NEUROLOGICAL DISEASES								
NUPLAZID® ¹	Parkinson's Disease Psychosis	5HT2A inverse agonist and antagonist						
ACP-204 ³	Alzheimer's Disease Psychosis	New 5HT2A inverse agonist						
ACP-204 ³	Lewy Body Dementia w/ Psychosis	New 5HT2A inverse agonist						
ACP-711 ^{3, 4}	Essential Tremor	Selective GABAA-α3 modulator						
ACP-211 ³	Major Depressive Disorder	Deuterated R-norketamine						
ACP-271 ³	Tardive Dyskinesia	GPR88 agonist						
RARE DISEASES								
DAYBUE® ²	Rett Syndrome	Analogue of GPE						
ACP-2591 ³	Rett Syndrome; Fragile X Syndrome	cGP analogue						
ACP-271 ³	Huntington's Disease	GPR88 agonist						
STOKE ASO ^{3, 5}	SYNGAP1	Antisense oligonucleotide (ASO)						

¹ NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

² Acadia has an exclusive license to develop and commercialize trofinetide worldwide from Neuren Pharmaceuticals. DAYBUE (trofinetide) is only approved in the U.S. by the FDA and in Canada by Health Canada for the treatment of Rett syndrome in adults and pediatric patients two years of age and older.

³ Investigational agents, for which the safety and efficacy of these agents have not been established. There is no guarantee these investigational agents will be filed with or approved by any regulatory agency.

⁴ Acadia entered into an exclusive worldwide license agreement with Saniona for the development and commercialization of ACP-711.

⁵ Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases; ASO = Antisense oligonucleotide.

